President Biden Signs Inflation Reduction Act Into Law
Former President Joe Biden signed The Inflation Reduction Act in the State Dining Room of the White House on August 16, 2022, in Washington, DC. The $737 billion bill focuses on climate change, lower healthcare costs, and creating clean energy jobs. Tens of thousands of Medicare beneficiaries who are cancer patients have substantially lower out-of-pocket costs for their prescription drugs, thanks to a key provision included in the Inflation Reduction Act.
The IRA’s drug pricing measures not only include Medicare price negotiation but also a redesign of Medicare’s outpatient drug benefit. This restructuring is already having an impact on Medicare recipients, especially beneficiaries who incurred more than $3,300 in annual out-of-pocket costs prior to 2024. Under the IRA law, annual out-of-pocket costs were capped at $3,300 in 2024 and lowered even further to $2,000 in 2025.
Since the enactment of the Medicare Modernization Act in 2006, Medicare beneficiaries have had access to a prescription drug benefit called Part D. This benefit aimed to help beneficiaries afford their outpatient medicines by offering coverage from prescription drug plans or fully integrated insurers under Medicare Advantage.
However, gaps in Part D coverage and high out-of-pocket costs in the catastrophic phase of the benefit posed challenges for beneficiaries, especially those taking expensive medications. The IRA, passed in 2022, includes a provision to decrease the out-of-pocket cost burden for Medicare recipients, capping annual expenses at $3,300 in 2024 and $2,000 in 2025.
A recent report reveals the importance of capping out-of-pocket beneficiary expenses, showing a significant increase in patient co-payments with the implementation of these caps. The management of costs in the catastrophic phase has shifted towards plans and drug manufacturers, with pharmaceutical manufacturers now covering 20% of drug costs in the catastrophic phase starting in 2025.
While the IRA has faced criticism, particularly regarding Medicare drug price negotiations and unintended consequences of Part D redesign, it has undeniably helped oncology patients with high out-of-pocket costs. Beneficiaries who were once burdened financially and struggling to afford their medications can now access and stay on their medication regimen without the fear of high out-of-pocket expenses.
Overall, the IRA’s changes in the design of the pharmacy benefit have enhanced incentives to contain costs while ensuring that all cancer medications are covered for Medicare beneficiaries. This legislation represents a significant step towards reducing healthcare costs and improving access to essential medications for those who need it most.
